Eli Lilly and Company (LLY)vsStevanato Group SpA (STVN)
LLY
Eli Lilly and Company
$1,208.12
+7.13%
HEALTHCARE · Cap: $1.08T
STVN
Stevanato Group SpA
$18.39
-0.27%
HEALTHCARE · Cap: $4.98B
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 5904% more annual revenue ($72.25B vs $1.20B). LLY leads profitability with a 35.0% profit margin vs 11.7%. LLY appears more attractively valued with a PEG of 1.46. LLY earns a higher WallStSmart Score of 78/100 (B+).
LLY
Strong Buy78
out of 100
Grade: B+
STVN
Hold46
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for LLY.
Margin of Safety
+64.0%
Fair Value
$43.34
Current Price
$18.39
$24.95 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 81 in profit
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 49.4%
Revenue surging 55.5% year-over-year
Earnings expanding 169.9% YoY
Conservative balance sheet, low leverage
Reasonable price relative to book value
Areas to Watch
Elevated debt levels
Premium valuation, high expectations priced in
Trading at 34.6x book value
Premium valuation, high expectations priced in
2.9% earnings growth
Weak financial health signals
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 35.0% and operating margin at 49.4%. Revenue growth of 55.5% demonstrates continued momentum.
Bull Case : STVN
The strongest argument for STVN centers on Debt/Equity, Price/Book.
Bear Case : LLY
The primary concerns for LLY are Debt/Equity, P/E Ratio, Price/Book. A P/E of 42.9x leaves little room for execution misses.
Bear Case : STVN
The primary concerns for STVN are P/E Ratio, EPS Growth, Piotroski F-Score.
Key Dynamics to Monitor
LLY profiles as a growth stock while STVN is a value play — different risk/reward profiles.
STVN carries more volatility with a beta of 0.78 — expect wider price swings.
LLY is growing revenue faster at 55.5% — sustainability is the question.
LLY generates stronger free cash flow (3.0B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (78/100 vs 46/100), backed by strong 35.0% margins and 55.5% revenue growth. STVN offers better value entry with a 64.0% margin of safety. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Stevanato Group SpA
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Stevanato Group SpA (STVN) is a premier global supplier of advanced drug delivery systems, catering to the pharmaceutical and biotechnology industries with innovative, high-quality glass and polymer packaging solutions for injectable medications. With a strong focus on quality, sustainability, and the integration of cutting-edge technology, the company is strategically positioned to capitalize on the increasing demand within the biopharmaceutical sector. Stevanato's commitment to enhancing the efficiency and reliability of drug administration underscores its potential as a compelling investment choice for institutional investors seeking exposure to healthcare innovation and sustainable growth.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?